Prevention of End-Stage Renal Disease Due to Type 2 Diabetes
- 20 September 2001
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 345 (12) , 910-912
- https://doi.org/10.1056/nejm200109203451209
Abstract
The prevalence of end-stage renal disease is increasing at an alarming rate. In 2000, chronic kidney failure developed in over 90,000 people in the United States; the current population of patients on dialysis numbers about 300,000, and 80,000 patients are living with transplanted kidneys. Both the prevalence and the incidence of end-stage renal disease are approximately twice what they were 10 years ago.1 Indeed, in 2000, the number of patients with newly diagnosed renal failure exceeded the number who died of any single type of cancer except lung cancer. Nephropathy due to type 2 diabetes accounts for almost all of . . .Keywords
This publication has 14 references indexed in Scilit:
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal DiseaseAnnals of Internal Medicine, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular DysfunctionNew England Journal of Medicine, 2001
- Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?Annals of Internal Medicine, 2001
- Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ, 2000
- Nephropathy in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 1999
- Use of Enalapril To Attenuate Decline in Renal Function in Normotensive, Normoalbuminuric Patients with Type 2 Diabetes MellitusAnnals of Internal Medicine, 1998